



**SUPPLEMENTAL FIGURE 1.** *In vitro* inhibition of <sup>125</sup>I-echistatin binding to integrin on U87MG cells by c(RGDfV), <sup>nat</sup>Cu-CB-TE2A-c(RGDfK), <sup>nat</sup>Cu-NODAGA-c(RGDfK), <sup>nat</sup>Cu-DOTA-c(RGDfK), <sup>nat</sup>Ga-NODAGA-c(RGDfK) and <sup>nat</sup>Ga-DOTA-c(RGDfK) (n = 3, mean±SD).



**SUPPLEMENTAL FIGURE 2.** Biodistribution results of  $^{64}\text{Cu}$ -NODAGA-c(RGDfK) in nude mice bearing U87MG tumors at 1, 4 and 18 h post-injection. Data are expressed as %IA/g  $\pm$  SD (n = 4–7).



**SUPPLEMENTAL FIGURE 3.** Whole body clearance of  $^{64}\text{Cu}$ -NODAGA-c(RGDfK) in nude mice. Data are expressed as %IA  $\pm$  SD (n=3). There is bi-exponential clearance with 75% of the activity cleared with a half-life of 15 minutes and 25% of the activity cleared with a half-life of 6 hours.